Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics third quarter 2024 financial results conference call. At this time, all parties are in a listen only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press the star key followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star then zero for operator assistance. As a reminder, this conference is being recorded today, October 23rd, 2024. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Land, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call, today, October 23, 2024, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely. and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments.

Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the three and nine months ended September 30, 2024, and provide an update on recent progress with our clinical programs and operations. The first three quarters of 2024 have been data-rich for Viking, with the company delivering positive data from four clinical programs, as well as promising in vivo data from a new preclinical program. Beginning in the first quarter, we announced positive results from the Phase II Ventra trial, evaluating subcutaneous VK2735 for the treatment of obesity. This trial demonstrated impressive reductions in body weight after 13 weeks of treatment. We also announced the initial results from a 28-day Phase I trial, evaluating a novel oral formulation of this compound, showing excellent tolerability and encouraging reductions in body weight. During the second quarter, the company announced histology results from the Phase IIb Voyage study, evaluating VK2809 for the treatment of NASH and fibrosis. This study successfully achieved its primary, secondary, and exploratory endpoints, showing reductions in liver fat at 12 weeks and improvement in NASH resolution rate and fibrosis after 52 weeks. Also during the second quarter, Viking announced in vivo results from a series of internally developed dual agonists of the amylin and calcitonin receptors. These compounds demonstrated body weight reductions, decreased food intake, and improved metabolic profile in animal models. Finally, subsequent to the end of the third quarter, we announced positive results from a 28-day Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy, or XALD. Results from this study showed VK0214 to be safe and well-tolerated following once-daily oral dosing over the 28-day treatment period. In addition, significant reductions were observed in plasma levels of very long-chain fatty acids and other lipids as compared to placebo. We are proud of the clinical progress we've made this year and look forward to further advancement of our pipeline programs in the quarters ahead. I'll have additional comments on our operations and development activities after we review our financial results for the third quarter and nine months ending September 30th. For that, I'll turn the call over to Greg Zanti, Vikings Chief Financial Officer. Thanks, Brian.